Literature DB >> 10334429

Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities.

B J Maron1, R Mathenge, S A Casey, L C Poliac, T F Longe.   

Abstract

OBJECTIVES: The purpose of this study was to assess the extent to which hypertrophic cardiomyopathy (HCM) exists unsuspected and undetected in the general population.
BACKGROUND: Hypertrophic cardiomyopathy is a disease with diverse natural history for which the potential to produce adverse consequences has been emphasized. However, the possibility of this disease remaining clinically dormant for many years has not been as widely appreciated. Certainly, the clinical recognition of previously undiagnosed patients with HCM may be advantageous by permitting risk stratification for sudden cardiac death or for timely pharmacologic therapy when symptoms intervene.
METHODS: We prospectively conducted an echocardiographic survey in 64 primarily rural communities within Minnesota (populations < 10,000) over a 33-month period.
RESULTS: A total of 15,137 echocardiograms were performed at the request of primary care physicians for the purpose of excluding cardiovascular abnormalities. Hypertrophic cardiomyopathy was identified in 44 patients during the survey (0.29%), and 29 of these patients (0.19% of the 15,137 echocardiograms) had not been previously identified as having cardiac disease or HCM. At diagnosis, ages were 16 to 87 years (mean 57); 14 patients were > or = 60 years of age, and only two were < 30 years. Twenty-four patients (83%) had either no or only mild or transient symptoms; 5 (17%) evidenced severe functional limitation; in eight patients the onset of symptoms had been deferred until > or = 70 years of age. Basal left ventricular outflow obstruction (gradients 20 to 82 mm Hg) was evident in 11 patients (38%). Relatively mild phenotypic expression of the disease was substantiated by localized patterns of left ventricular wall thickening occurring more commonly than diffusely distributed hypertrophy (48% vs. 7%, respectively), and electrocardiograms that were frequently normal (about 25%) and rarely showed evidence of left ventricular hypertrophy (10%).
CONCLUSIONS: These prospectively assembled data show that HCM may remain clinically dormant and undetected within community-based rural populations for many years (often to advanced ages) with a not inconsequential prevalence similar to that of HCM in the general population.

Entities:  

Mesh:

Year:  1999        PMID: 10334429     DOI: 10.1016/s0735-1097(99)00039-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

1.  The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited.

Authors:  B J Maron
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-10       Impact factor: 1.468

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy.

Authors:  A Selcuk Adabag; Barry J Maron
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

Review 4.  [Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].

Authors:  D Duncker; T König; S Hohmann; C Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

5.  A painful diagnosis.

Authors:  Paolo Fraticelli; Marco Cardinali; Lorenzo Biondi; Devis Benfaremo; Massimo Mattioli; Roberta Mazzucchelli; Rodolfo Montironi; Armando Gabrielli
Journal:  Intern Emerg Med       Date:  2017-02-25       Impact factor: 3.397

6.  Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts.

Authors:  Alexander G Bick; Jason Flannick; Kaoru Ito; Susan Cheng; Ramachandran S Vasan; Michael G Parfenov; Daniel S Herman; Steven R DePalma; Namrata Gupta; Stacey B Gabriel; Birgit H Funke; Heidi L Rehm; Emelia J Benjamin; Jayashri Aragam; Herman A Taylor; Ervin R Fox; Christopher Newton-Cheh; Sekar Kathiresan; Christopher J O'Donnell; James G Wilson; David M Altshuler; Joel N Hirschhorn; J G Seidman; Christine Seidman
Journal:  Am J Hum Genet       Date:  2012-09-07       Impact factor: 11.025

Review 7.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 8.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 9.  Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis.

Authors:  Angie Mae Rodday; John K Triedman; Mark E Alexander; Joshua T Cohen; Stanley Ip; Jane W Newburger; Susan K Parsons; Thomas A Trikalinos; John B Wong; Laurel K Leslie
Journal:  Pediatrics       Date:  2012-03-05       Impact factor: 7.124

Review 10.  Hypertrophic cardiomyopathy: genetics and clinical perspectives.

Authors:  Cordula Maria Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.